Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
IRVINE, Calif., Sept. 07, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE:RDY). Investors who purchased or otherwise acquired shares between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 24, 2017 lead plaintiff motion deadline.
If you purchased Dr. Reddy’s shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Dr. Reddy’s made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy’s lowered in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
